Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine.
Animals
Biological Specimen Banks
Biotechnology
/ methods
COVID-19 Vaccines
Cell Line
Cell- and Tissue-Based Therapy
Diploidy
History, 20th Century
History, 21st Century
Humans
Lung
/ cytology
Regeneration
Regenerative Medicine
/ history
Respiratory Tract Infections
/ therapy
SARS-CoV-2
Stem Cell Transplantation
Stem Cells
/ cytology
Transplantation, Homologous
COVID-19
MRC-5 cells
active pharmaceutical ingredient
cell banking
cell therapy
diploid progenitor cells
inflammatory lung disease
lung cells
regenerative medicine
vaccine substrate
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
24 09 2021
24 09 2021
Historique:
received:
20
08
2021
revised:
14
09
2021
accepted:
21
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
16
11
2021
Statut:
epublish
Résumé
The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration.
Identifiants
pubmed: 34685505
pii: cells10102526
doi: 10.3390/cells10102526
pmc: PMC8533713
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Historical Article
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Natl Cathol Bioeth Q. 2006 Autumn;6(3):541-37
pubmed: 17091557
Natl Cathol Bioeth Q. 2006 Autumn;6(3):473-95
pubmed: 17091554
Cytotherapy. 2014 Mar;16(3):289-97
pubmed: 24113428
Viruses. 2014 Apr 11;6(4):1672-700
pubmed: 24732259
Stem Cell Res Ther. 2020 Jun 3;11(1):213
pubmed: 32493487
Ethics Medics. 1999 Mar;24(3):3-4
pubmed: 11657845
Respir Res. 2018 Nov 9;19(1):218
pubmed: 30413158
Natl Cathol Bioeth Q. 2002 Spring;2(1):51-67
pubmed: 12854568
Biol Res. 2012;45(3):207-14
pubmed: 23283430
J Cell Mol Med. 2009 Aug;13(8B):2559-2569
pubmed: 19413893
J Aerosol Med Pulm Drug Deliv. 2014 Feb;27(1):30-4
pubmed: 23409833
Int J Mol Med. 2018 Mar;41(3):1463-1468
pubmed: 29328434
Front Cell Dev Biol. 2020 Dec 17;8:547653
pubmed: 33392179
Am J Hyg. 1962 Mar;75:240-58
pubmed: 13905660
Tissue Eng Part A. 2011 Jan;17(1-2):5-15
pubmed: 20726816
Methods Mol Biol. 2021;2286:25-48
pubmed: 32468492
J Control Release. 2019 Sep 10;309:11-24
pubmed: 31326462
Hum Vaccin. 2010 Feb;6(2):178-88
pubmed: 19875936
Lancet. 1999 Jul;354 Suppl 1:SI32-4
pubmed: 10437854
Cytotherapy. 2016 Jun;18(6):797-805
pubmed: 27068764
Stem Cells Transl Med. 2016 Dec;5(12):1668-1675
pubmed: 27460855
J Biol Stand. 1979 Apr;7(2):113-22
pubmed: 113411
J Exp Med. 1929 Jul 31;50(2):181-7
pubmed: 19869613
Front Cell Dev Biol. 2020 May 19;8:316
pubmed: 32509777
Pediatr Surg Int. 2008 Jan;24(1):37-47
pubmed: 17962961
N Engl J Med. 2018 Mar 8;378(10):954-959
pubmed: 29514023
Pharmaceutics. 2021 Feb 07;13(2):
pubmed: 33562240
Int J Mol Sci. 2020 Apr 30;21(9):
pubmed: 32366033
Acta Biochim Biophys Sin (Shanghai). 2020 Jul 10;52(7):716-722
pubmed: 32445469
Ann Neurol. 2007 May;61(5):385-95
pubmed: 17469121
Stem Cells Dev. 2020 Jun 15;29(12):747-754
pubmed: 32380908
Stem Cell Res Ther. 2020 Oct 15;11(1):437
pubmed: 33059757
Exp Cell Res. 1965 Mar;37:614-36
pubmed: 14315085
Vaccine. 2010 Dec 6;28(52):8246-55
pubmed: 21036129
Cell Prolif. 2020 Dec;53(12):e12939
pubmed: 33098357
Skin Pharmacol Physiol. 2009;22(2):63-73
pubmed: 19188754
Cytotherapy. 2018 Jan;20(1):108-125
pubmed: 29056548
Vaccine. 2014 Nov 28;32(50):6820-7
pubmed: 25086263
Cell Transplant. 2006;15(8-9):823-34
pubmed: 17269452
Natl Cathol Bioeth Q. 2006 Autumn;6(3):453-9
pubmed: 17091552
Hum Vaccin Immunother. 2015;11(4):998-1009
pubmed: 25803132
Linacre Q. 2004 Nov;71(4):335-50
pubmed: 15685774
Vaccine. 2003 Jan 30;21(7-8):596-600
pubmed: 12531324
Front Bioeng Biotechnol. 2020 Jun 19;8:581
pubmed: 32637400
Regen Ther. 2015 Feb 19;1:30-37
pubmed: 31245439
Cell Transplant. 2007;16(7):675-84
pubmed: 18019357
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Lancet. 2005 Sep 3-9;366(9488):840-2
pubmed: 16139659
Nature. 1970 Jul 11;227(5254):168-70
pubmed: 4316953
Stem Cells Dev. 2020 Jun 1;29(11):679-681
pubmed: 32292113
Hum Gene Ther. 2000 Oct 10;11(15):2105-16
pubmed: 11044912
Artif Organs. 2008 Jul;32(7):509-18
pubmed: 18638304
Methods Mol Biol. 2021;2286:1-24
pubmed: 32430595
Nature. 1972 Oct 6;239(5371):316-8
pubmed: 12635218
Methods Mol Biol. 2021;2286:49-65
pubmed: 32572700
Cell Med. 2012 May 08;4(1):23-32
pubmed: 26858853
Front Bioeng Biotechnol. 2020 Oct 23;8:557758
pubmed: 33195124
ISRN Dermatol. 2011;2011:549870
pubmed: 22363853
Biotechnol Bioeng. 2003 Jul 5;83(1):45-52
pubmed: 12740932
Exp Gerontol. 2009 Mar;44(3):208-18
pubmed: 19049860
Nature. 1974 Oct 4;251(5474):434-6
pubmed: 4423711
Ann Pharmacother. 2003 Sep;37(9):1340-1
pubmed: 12921522
Pharmaceuticals (Basel). 2021 Feb 28;14(3):
pubmed: 33671009
Ann Burns Fire Disasters. 2016 Jun 30;29(2):111-115
pubmed: 28149232
Vaccine. 2013 Apr 12;31(16):2011-23
pubmed: 23499565
Exp Cell Res. 1961 Dec;25:585-621
pubmed: 13905658
Stem Cell Rev Rep. 2019 Feb;15(1):112-125
pubmed: 30178289